Test Code APROL Prolonged Clot Time Profile, Plasma
Reporting Name
Prolonged Clot Time ProfPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Determining the cause of prolongation of prothrombin time or activated partial thromboplastin time
Screening for prolonged clotting times and determining the presence of factor deficiencies or inhibitor (eg, factor-specific, lupus-like, or the presence of heparin)
Method Name
ARPI: Medical Interpretation
PTSC, APTSC, DRV1, TTSC, GBETH, 5BETH, 8BETH, 9BETH, F8IS, FACTV, F_2, F_7, F_9, F_10, F_11, F_12, F8A, RTSC, PNP, APMSC, PTMSC, PTFIB, DRV2, DRV3: Optical Clot-Based
CLFIB: Clauss
DIMER, SOLFM: Latex Immunoassay (LIA)
CH9, CHF8: Chromogenic
HEXLA: Spectrophotometric
Ordering Guidance
Multiple coagulation profile tests are available. See Coagulation Profile Comparison for testing that is performed with each profile.
Shipping Instructions
Send the 5 aliquots in the same shipping container.
Necessary Information
Note if patient is currently receiving heparin, Coumadin (warfarin) or any medication affecting coagulation.
Specimen Required
Specimen Type: Platelet-poor plasma
Patient Preparation:
1. Patient should not be receiving anticoagulant treatment (eg, warfarin, heparin). Treatment with heparin causes false-positive results of in vitro coagulation testing for lupus anticoagulant. Coumadin (warfarin) treatment may impair ability to detect the more subtle varieties of lupus-like anticoagulants.
2. Patient should also not be receiving fibrinolytic agents (streptokinase, urokinase, tissue plasminogen activator [tPA]).
3.It is best to perform this study pretransfusion if possible. If patient has been recently transfused, wait at least 48 hours after transfusion to collect the specimen.
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 5 mL in 5 plastic vials, each containing 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma (1-2 mL per aliquot) into 5 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Specimen Type
Plasma Na CitSpecimen Minimum Volume
4 plastic vials, each containing 1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
An interpretive report will be provided.
Interpretation
An interpretive report will be provided when testing is completed, noting a presence or absence of a prolonged bleeding disease state.
Day(s) Performed
Monday through Friday
Report Available
3 to 7 daysTest Classification
See Individual Test IDsCPT Code Information
85379-DIMER
85384-CLFIB
85390-26-APRI
85610-PTSC
85613-DRV1
85670-TTSC
85730-APTSC
85130-Chromogenic FVIII (if appropriate)
85130-Chromogenic FIX (if appropriate)
85210-Factor II (if appropriate)
85220-Factor V (if appropriate)
85230-Factor VII (if appropriate)
85240-Factor VIII (if appropriate)
85250-Factor IX (if appropriate)
85260-Factor X (if appropriate)
85270-Factor XI (if appropriate)
85280-Factor XII (if appropriate)
85335-Bethesda titer (if appropriate)
85335-Factor V inhibitor screen (if appropriate)
85335-Factor VIII inhibitor screen (if appropriate)
85335-Factor IX inhibitor screen (if appropriate)
85366-Soluble fibrin monomer (if appropriate)
85385-PT-Fibrinogen (if appropriate)
85597-Platelet neutralization for lupus inhibitor (if appropriate)
85598-Hex LA (if appropriate)
85611-PT mix 1:1 (if appropriate)
85613-DRVVT mix (if appropriate)
85613-DRVVT confirm (if appropriate)
85635-Reptilase time (if appropriate)
85732-APTT mix 1:1 (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
APROL | Prolonged Clot Time Prof | 98125-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
603324 | Reviewed by | 18771-6 |
CLFIB | Fibrinogen, Clauss, P | 48664-7 |
RVR1 | DRVVT Screen Ratio | 15359-3 |
TTSC | Thrombin Time (Bovine), P | 46717-5 |
APTSC | Activated Partial Thrombopl Time, P | 14979-9 |
PTSEC | Prothrombin Time (PT), P | 5902-2 |
603183 | Prolonged Clot Time Prof Interp | 69049-5 |
DIMER | D-Dimer, P | 48067-3 |
INRSC | INR | 6301-6 |
Forms
1. Coagulation Patient Information (T675)
2. If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
APRI | Prolonged Clot Time Prof Interp | No | Yes |
PTSC | Prothrombin Time (PT), P | Yes, (order PTTP) | Yes |
APTSC | Activated Partial Thrombopl Time, P | Yes, (order APTTP) | Yes |
DRV1 | Dilute Russells Viper Venom Time, P | Yes, (order DRVI1) | Yes |
TTSC | Thrombin Time (Bovine), P | Yes | Yes |
CLFIB | Fibrinogen, Clauss, P | Yes, (order FIBTP) | Yes |
DIMER | D-Dimer, P | Yes, (order DDITT) | Yes |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
GBETH | General Factor Bethesda Units, P | No | No |
5BETH | FV Bethesda Units, P | No | No |
8BETH | FVIII Bethesda Units, P | No | No |
9BETH | FIX Bethesda Units, P | No | No |
F8IS | Coag Factor VIII Assay Inhib Scrn,P | No | No |
FACTV | Coag Factor V Assay, P | Yes | No |
F_7 | Coag Factor VII Assay, P | Yes | No |
F_9 | Coag Factor IX Assay, P | Yes | No |
F_10 | Coag Factor X Assay, P | Yes | No |
F_11 | Coag Factor XI Assay, P | Yes | No |
F_12 | Coag Factor XII Assay, P | Yes | No |
F8A | Coag Factor VIII Activity Assay, P | Yes | No |
RTSC | Reptilase Time, P | Yes | No |
F_2 | Coag Factor II Assay, P | Yes | No |
PNP | Platelet Neutralization Procedure | No | No |
PTMSC | PT Mix 1:1 | No | No |
APMSC | APTT Mix 1:1 | No | No |
DRV2 | DRVVT Mix | No | No |
DRV3 | DRVVT Confirmation | No | No |
F5_IS | Factor V Inhib Scrn | No | No |
F9_IS | Factor IX Inhib Scrn | No | No |
F2_IS | Factor II Inhib Scrn | No | No |
F7_IS | Factor VII Inhib Scrn | No | No |
10_IS | Factor X Inhib Scrn | No | No |
11_IS | Factor XI Inhib Scrn | No | No |
PTFIB | PT-Fibrinogen, P | No | No |
SOLFM | Soluble Fibrin Monomer | No | No |
CH9 | Chromogenic FIX, P | Yes | No |
CHF8 | Chromogenic FVIII, P | Yes | No |
HEXLA | HEX LA, P | No | No |
Testing Algorithm
Initial testing includes prothrombin time (PT), activated partial thromboplastin time (aPTT), dilute Russell's viper venom time (dRVVT), thrombin time (bovine), fibrinogen, D-dimer, and prolonged clot time interpretation.
If PT is greater than 13.9 seconds, then PT mix will be performed at an additional charge.
If aPTT is greater or equal to 38 seconds, then aPTT mix will be performed at an additional charge.
If aPTT mix is greater or equal to 38 seconds and thrombin time is less than 35.0 seconds (no evidence of heparin), then platelet neutralization procedure will be performed at an additional charge.
If dRVVT ratio is greater or equal to 1.20, then dRVVT mix and dRVVT confirmation will be performed at an additional charge.
If thrombin time is greater or equal to 25.0 seconds, then reptilase time will be performed at an additional charge.
If fibrinogen is less than 150 mg/dL or clinically indicated, then PT-fibrinogen will be performed at an additional charge.
If D-dimer is greater than 500 ng/mL fibrinogen equivalent units, then soluble fibrin monomer will be performed at an additional charge.
If PT, aPTT, or dRVVT is prolonged, then coagulation factor assays may be performed at an additional charge.
If factor assay result is below the normal range, the appropriate factor inhibitor screen may be performed along with the Bethesda titering assay, at an additional charge, if inhibitor screen is positive.
If appropriate, hexagonal lupus anticoagulant will be performed at an additional charge to clarify significant abnormalities in the screen test results.